To determine the potential efficacy of KRAS inhibition against MPE, the novel KRAS inhibitor deltarasin30 was administered daily intraperitoneally at 15 mg kg−1, side-by-side with a saline control treatment, to mice with established pleural tumours. The gene discussed is KRAS; the disease is pleural neoplasm.